EQS-News: M1 Kliniken AG publishes Half-Year Report 2026: Beauty EBIT up 23.8% to EUR 18.6 million
|
EQS-News: M1 Kliniken AG
/ Key word(s): Half Year Report/Half Year Results
M1 Kliniken AG publishes Half-Year Report 2026: Beauty EBIT up 23.8% to EUR 18.6 million Berlin, 9 September 2026 – M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its report for the first half of 2026. In its core business “Beauty”, the Group further improved its operating performance while completing its strategic refocusing. Revenue in the Beauty segment rose by 11.0% to EUR 56.9 million, while segment EBIT increased at a faster rate, rising by 23.8% to EUR 18.6 million. With the sale of HAEMATO Pharm GmbH to the PHOENIX group by the 85%-owned M1 Aesthetics AG (formerly HAEMATO AG), completed as of 31 January 2026, the exit from the trading business is complete.
Due to the sale of HAEMATO Pharm GmbH, the Group figures are only partially comparable with the prior-year period; revenue from the divested business is included for January 2026 only. Reported EBIT of EUR 15.6 million also includes a one-off, non-cash deconsolidation effect of EUR -4.1 million. Adjusted for this special item, EBIT reached EUR 19.7 million, 9.5% above the prior-year figure. Beauty segment: growth and profitability increased again
The Beauty segment remains the Group’s central driver of growth and earnings. This performance was supported by efficiency gains in operating processes and the targeted expansion of medical capacity. With an EBIT margin of 32.7%, the core business continues to clearly exceed its medium-term margin target of at least 20%. Trading segment: planned exit completed
The sharp decline in the trading business is the direct consequence of the sale of HAEMATO Pharm GmbH. Outlook M1 Kliniken AG will consistently pursue its profitable growth path through the expansion of national and international clinics. For the Beauty segment, the company is targeting revenue of EUR 200 to 300 million by 2029 with a sustainable EBIT margin of at least 20%. The overarching goal remains to establish M1 Med Beauty as the world’s leading brand for aesthetic medicine. About M1 Kliniken AG M1 Kliniken AG is the leading fully integrated provider of aesthetic medicine services in Europe and Australia. With a clearly focused business model, a high degree of standardisation and consistent scaling, the Group currently operates 59 clinics in ten countries under the M1 Med Beauty brand. All treatments are performed exclusively by qualified physicians in accordance with uniformly high quality standards and are offered at market-leading prices. The international expansion, pursued systematically since the end of 2018, forms the basis for further scalable growth and the strengthening of the Group’s global market position. With the M1 Schlossklinik in Berlin, the Group operates one of the largest and most modern clinics for plastic and aesthetic surgery in Europe. The facility has four operating theatres and 35 beds. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
09.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| LEI Code: | 529900W697S31A26WT02 |
| EQS News ID: | 2396142 |
| End of News | EQS News Service |
|
|
2396142 09.09.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 159,59 | 314,61 | 285,29 | 316,32 | 339,18 | 364,30 | 145,00 | |
| EBITDA1,2 | 8,89 | 17,82 | 15,41 | 21,01 | 31,96 | 39,44 | 36,00 | |
| EBITDA-Margin3 | 5,57 | 5,66 | 5,40 | 6,64 | 9,42 | 10,83 | 24,83 | |
| EBIT1,4 | 4,41 | 12,13 | 9,35 | 15,70 | 26,75 | 34,56 | 32,00 | |
| EBIT-Margin5 | 2,76 | 3,86 | 3,28 | 4,96 | 7,89 | 9,49 | 22,07 | |
| Net Profit (Loss)1 | 7,43 | 10,88 | 7,07 | 11,67 | 17,79 | 24,10 | 25,00 | |
| Net-Margin6 | 4,66 | 3,46 | 2,48 | 3,69 | 5,25 | 6,62 | 17,24 | |
| Cashflow1,7 | 9,54 | 15,68 | 20,77 | 7,81 | 30,55 | 37,95 | 39,00 | |
| Earnings per share8 | 0,37 | 0,45 | 0,22 | 0,54 | 0,85 | 1,19 | 1,24 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,50 | 0,50 | 1,20 | 0,60 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: wetreu NTRG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| M1 Kliniken | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0STSQ | DE000A0STSQ8 | AG | 393,37 Mio € | 14.09.2015 | Kaufen | 9F4MCHV9+6R |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 15,59 | 25,48 | 0,61 | 34,25 | 3,86 | 10,37 | 1,08 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,50 | 0,50 | 1,20 | 5,66% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 08.07.2026 | 03.06.2026 | 09.09.2026 | 18.11.2026 | 20.05.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +13,64% | +20,94% | +11,58% | +56,80% | +351,06% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
